United States: The Federal Circuit's First Foray Into The BPCIA: "A Pulitzer Prize For Complexity"?

Last Updated: June 5 2015
Article by Thomas H. Wintner

Yesterday, a Federal Circuit panel comprising Judges Newman, Lourie, and Chen heard oral argument in Amgen Inc. v. Sandoz Inc. (Fed. Cir. No. 2015-1499), the first ever case requiring the Appeals Court to address the meaning of various provisions of the Biologics Price Competition and Innovation Act (BPCIA). The appeal was fast-tracked because of the potentially imminent marketing of Sandoz's Zarxio® (filgrastim-sndz), which is a biosimilar version of Amgen's Neupogen® (filgrastim) and is the first biosimilar to receive FDA approval under the BPCIA.

As expected, the panel's questions focused on two primary issues, both of which were decided largely in Sandoz's favor during the district court proceedings:

  1. Whether the BPCIA's patent exchange provisions – specifically, 42 U.S.C. § 262(l)(2)-(6) – are mandatory (Amgen's view) or optional (Sandoz's view), and what the consequences of non-compliance or "opting out" should be;
  2. Whether the 180-day pre-launch notice required under 42 U.S.C. § 262(l)(8) may be given immediately upon FDA's acceptance of the biosimilar application (Sandoz's view) or only upon FDA's approval of the application (Amgen's view).

The panel tested both sides of both arguments. With regard to the mandatory versus optional debate, the panel seemed concerned that use of the term "shall" in § 262(l)(2) – i.e., "the subsection (k) applicant shall provide to the reference product sponsor a copy of the application submitted to the Secretary under subsection (k) and such other information that describes the process or processes used to manufacture the biological product" – could under Sandoz's interpretation of the statute be disregarded, thus rendering much of the BPCIA's complex patent exchange process a waste of legislative breath. The panel questioned why Congress would have created these patent exchange procedures if they could be circumvented entirely, or if selected procedures could be skipped like in a game of "choose your own adventure." On the other hand, some members of the panel questioned Amgen's basis for claiming a remedy different from that provided in § 262(l)(9)(C), which is specifically directed to the situation in which a biosimilar applicant "fails to provide the application and information required under [§ 262(l)(2)(A)]."

With regard to the timing of the 180-day notice of commercial marketing, the panel asked why it made sense for Amgen to enjoy what effectively would be an additional six months of exclusivity if the Court were to decide that 180-day notice could be given only after FDA's approval of the biosimilar drug. On the other hand, the panel seemed perplexed that allowing the required 180-day notice to be given already upon FDA's acceptance of the biosimilar application (which is what Sandoz and other biosimilar applicants appear to have done) would make the notice "entirely speculative" and merely "aspirational." It is true, for example, that FDA approved Sandoz's Zarxio® product relatively quickly and along the timeline that Sandoz seems to have anticipated. But that does not mean the same will hold for all biosimilar applications – and indeed FDA approvals of other applications, such as Celltrion's application for a biosimilar infliximab product, have already been delayed due to requests from FDA for additional information.

The Federal Circuit panel also seemed interested in several questions related to "linkage." First, the panel questioned whether there was any statutory linkage between § 262(k), governing "Licensure," and § 262(l), governing "Patents." Second, the panel asked about linkage between § 262(k) and (l) and 35 U.S.C. § 271(e)(2)(C), which, like the related provisions of the Hatch-Waxman Act, provides a statutory basis for asserting infringement even in the absence of a marketed product. The panel focused on understanding when infringement occurs given that § 271(e)(2)(C) generally provides a statutory basis for infringement upon submission of a § 262(k) application, and yet the predicate patents for such a suit can only be identified via an exchange process that necessarily occurs after submission of the application. These linkage questions, as well as issues of BPCIA preemption and private rights of action, likely will be the subject of future litigation – such as Janssen Biotech v. Celltrion Healthcare, No. 15-10698 (D. Mass.).

The panel was in full agreement on one conclusion: that the BPCIA sets forth a complicated statutory regime. One panel member went so far as to say that the statute deserves "a Pulitzer Prize for complexity." The panel also seemed sensitive to the need to interpret the BPCIA not just for this particular case (which involves a reference product for which the statutory 12-year exclusivity has long since expired), but for all cases that might arise under the BPCIA, including ones in which there might be considerably more time for the parties to litigate patent issues prior to FDA's first effective approval date of a biosimilar application.

Sorting through all of these issues will be no small task for the Federal Circuit panel, and thus possibilities remain for subsequent review by the Federal Circuit sitting en banc or even by the U.S. Supreme Court. For now, however, the Appeals Court has enjoined Sandoz from marketing its approved Zarxio® product, so we are unlikely to see the first biosimilar test the consumer market until the Appeals Court makes a decision. When the first biosimilar does enter the market, regulators and health care practitioners alike will have other issues to contend with, such as the reimbursement formula and any dispensing restrictions that may apply, as my colleagues in the Mintz Levin Health Law Practice discuss in a recent  BNA Medicare Report article and on the Health Law and Policy Matters blog.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions